Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 83

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 83
---

Consolidated 

  Three months ended  Nine months ended   September 30,  September 30,   2025  2024  2025  2024              REVENUE (including $25,649 and $23,456 of revenue from related parties for the three months period ended September 30, 2025 and 2024 respectively, including $57,632 and $65,380 of revenue from related parties for the nine months period ended September 30, 2025 and 2024 respectively) $2,543,823  $2,630,376  $6,941,151  $6,986,791    -   -         COST OF REVENUE (including $7,233 and $192,171 of cost of revenue from related parties for the three months period ended September 30, 2025 and 2024, respectively, including $9,404 and $293,770 of cost of revenue from related parties for the nine months period ended ended September 30, 2025 and 2024, respectively)  (2,166,138)  (2,303,840)  (5,851,951)  (6,006,504)       -         GROSS PROFIT  377,685   326,536   1,089,200   980,287        -         OTHER INCOME      -         Dividend income   4,192   38,826   21,752   59,653 Interest income  20,778   35,022   74,114   113,744 Fair value gain on investments in equity securities  -   69,765   28,256   243,083 Gain on disposal of investments in equity securities  42,376   20,800   42,376   35,098 Reversal of expected credit losses  -   257,986   94,912   842,401 Others  40,414   43,128   147,231   103,500 TOTAL OTHER INCOME  107,760   465,527   408,641   1,397,479                  OPERATING EXPENSES